What Hologic (HOLX) Investors Need to Know Today

Shares of Healthcare sector company Hologic moved -1.6% today, and are now trading at a price of $79.76. The large-cap stock's daily volume was 1,031,278 compared to its average volume of 1,619,230. The S&P 500 index returned a 0.4% performance.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. The company is based in Marlborough and has 6,944 full time employees. Its market capitalization is $19,607,719,936.

14 analysts are following Hologic and have set target prices ranging from $74 to $90 per share. On average, they have given the company a rating of buy. At today's prices, HOLX is trading -1.97% away from its average analyst target price of $81.36 per share.

Over the last year, HOLX's share price has increased by 15.9%, which represents a difference of 30.7% when compared to the S&P 500. The stock's 52 week high is $81.97 per share whereas its 52 week low is $59.78. With an average free cash flow of $1,360,575,000.0 that have been growing at an average rate of 74.4% over the last four years, Hologic is in a position to continue its strong stock performance trend.

Date Reported Cash Flow from Operations ($ MM) Capital expenditures ($ MM) Free Cash Flow ($ MM) YoY Growth (%)
2022-09-30 2,126 -127 1,998 -7.81
2021-09-30 2,330 -163 2,168 192.85
2020-09-30 897 -156 740 38.12
2019-09-30 650 -114 536 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.